Skip to main content

Table 3 Incidence of infections and corresponding pathogens

From: The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients

 

All

Taurolidine

High- concentrated citrate

Low-concentrated citrate

Number of patients (any CVC, %)a

1603

129 (8)

1132 (71)

317 (20)

Number of CVC in total (%)

2749

211 (8)

1840 (67)

490 (18)

Total number of CVC days (median, IQR)

271,295

40,671

166,819

43,533

Number of proven catheter-related BSI b (%)

225

15 (12)

149 (13)

36 (11)

Incidence rate of BSI per 1000 catheter daysc

0.83

0.37

0.89

0.83

Number of proven catheter-related BSI for femoral CVC (%)

16

2 (10)

9 (3)

5 (5)

Incidence rate of BSI per 1000 catheter days for femoral CVC

1.77

0.80

1.70

4.03

Type of pathogen during BSId

 Coagulase negative staphylococci (%)

72 (32)

5 (33)

46 (31)

11 (31)

S. aureus (%)

61 (27)

2 (13)

45 (30)

9 (25)

 Gram-negative (%)

43 (19)

4 (27)

30 (20)

6 (17)

 Gram-positive (%)

40 (18)

3 (20)

24 (16)

9 (25)

 Yeast (%)

2 (< 1)

1 (3)

  1. adifferent lock solutions within patients during different CVC possible. In this table, all consecutive CVC are taken in to account and patients who used citrate or taurolidine locks later on (not only first) lines were also included)
  2. b14 CVC with > 1 episode of BSI: 9 with citrate lock and 1 with taurolidine lock
  3. cfor all lines
  4. dmultiple pathogens per episode possible. Unknown pathogen in 14 positive cultures